Search clinical trials for: Ado-Trastuzumab Emtansine

Total 3611 results

Peking University Cancer Hospital & Institute

Not yet recruiting

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Breast Neoplasm Female
European Organisation for Research and Treatment...
Hoffmann-La Roche

Completed

Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Elderly Metastatic Breast Cancer Population

Belgium, Italy, Netherlands, France, Poland, United Kingdom, Portugal, Sweden
Byondis B.V.

Completed

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Endometrial Cancer

Korea, Republic of, Singapore, Russian Federation, Ukraine, United States, Poland, Serbia
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Advanced Melanoma | Melanoma, Stage II | HER2-positive

China
RemeGen Co., Ltd.

Active, not recruiting

A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

Sarcoma
Pfizer

Active, not recruiting

Safety and Efficacy of Trastuzumab BS

Gastric Cancer

Japan
Fudan University

Active, not recruiting

Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

Breast Cancer

China
M.D. Anderson Cancer Center

Completed

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

Ductal Carcinoma In Situ

United States
Hoffmann-La Roche

Terminated

A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

Urinary Tract Cancer

Germany
Hoffmann-La Roche

Terminated

A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer

Breast Cancer

Italy
Nantes University Hospital

Terminated

Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

Relapsed/Refractory Leukemia

France
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Gynecological Malignancy

China
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

Healthy

China
Alberto Espay, MD, MSc
Lundbeck LLC

Completed

Lundbeck TOMs Orthostatic Hypotension

Orthostatic Hypotension | Idiopathic Parkinson Disease

United States
Fudan University

Recruiting

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Metastatic Breast Cancer | HER2-positive Breast Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Malignant Solid Neoplasm

United States
Hoffmann-La Roche

Completed

A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe

Healthy Volunteer

New Zealand
University Medical Center Groningen

Completed

Clinical Value of 89Zr-trastuzumab PET

Metastatic Breast Cancer

Netherlands
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Recurrent Osteosarcoma

Sarcoma

United States
Sanofi

Completed

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

Breast Neoplasms

France, Sweden, Switzerland, Belgium
Washington University School of Medicine
Molecular Templates, Inc.

Withdrawn

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

HER2-positive Solid Tumor | HER-2 Positive Cancer
Hoffmann-La Roche

Completed

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

Breast Cancer

Italy, Austria, Belgium, Germany, Spain, United Kingdom, Hungary, Poland, Sweden
Hoffmann-La Roche

Terminated

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Gastric Cancer

India
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Regione Lombardia
Mario Negri Institute for Pharmacological Research; Istituto Clinico Humanitas

Unknown

Trastuzumab Optimization Trial in Breast Cancer (TOP)

Metastatic or Locally Advanced Breast Cancer

Italy
Fudan University

Not yet recruiting

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Triple-Negative Breast Cancer

China
RemeGen Co., Ltd.

Completed

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Advanced Cancer | Urothelial Carcinoma

China
Huihua Xiong

Not yet recruiting

A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

Breast Cancer
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Advanced Breast Cancer
Sanofi

Completed

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer

United States
Takeda

Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Alpha1-Antitrypsin Deficiency

Italy, United States, Poland, Portugal
Hoffmann-La Roche

Terminated

A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (LISAH)

Breast Cancer

Austria
National Cancer Institute (NCI)
NRG Oncology

Completed

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Metastatic Breast Cancer | Metastatic Gastric Cancer

China
Memorial Sloan Kettering Cancer Center
Novartis

Completed

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Breast Cancer

United States
Xuzhou Medical University

Unknown

Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer

Gastric Cancer

China
The University of Texas Health Science Center at...
National Cancer Institute (NCI)

Withdrawn

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

Breast Cancer
Hoffmann-La Roche

Completed

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Italy
University of Michigan Rogel Cancer Center

Terminated

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7 | ERBB2 Gene Amplification

United States
Shanghai Zhongshan Hospital

Not yet recruiting

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

HER2-positive Gastric Cancer
National University Hospital, Singapore
National University of Singapore

Unknown

NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer

Breast Cancer | Gastric Cancer

Singapore
Anglo Celtic Cooperative Oncology Group

Completed

Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer

Breast Cancer

United Kingdom
Warwick Medical School

Unknown

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

Breast Cancer

United Kingdom
Comprehensive Support Project for Oncology Research

Completed

National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT] (RESPECT)

Breast Cancer

Japan
Jules Bordet Institute

Completed

PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2

Carcinoma Breast Stage IV

Belgium
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Aventis Pharmaceuticals

Terminated

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

Breast Cancer

United States
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China

3

Subscribe